indacaterol-glycopyrronium combination

a dual bronchodilator consisting of the long-acting beta2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237) for treatment of patients with moderate to severe chronic obstructive pulmonary disease

Also Known As:

Networked: 32 relevant articles (9 outcomes, 15 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Banerji, Donald: 14 articles (11/2015 - 01/2013)
2.	Chen, Hungta: 8 articles (01/2015 - 01/2013)
3.	D'Andrea, Peter: 5 articles (10/2014 - 03/2013)
4.	Bateman, Eric D: 4 articles (01/2015 - 03/2013)
5.	Wedzicha, Jadwiga A: 4 articles (10/2014 - 05/2013)
6.	Alagappan, Vijay K T: 4 articles (06/2014 - 01/2013)
7.	Mahler, Donald A: 3 articles (11/2015 - 06/2014)
8.	Patalano, Francesco: 3 articles (11/2015 - 06/2014)
9.	Cazzola, Mario: 3 articles (05/2015 - 01/2015)
10.	Buhl, Roland: 3 articles (04/2015 - 12/2010)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 04/01/2014 - "In patients with moderate-to-severe COPD, once-daily QVA149 significantly improved exercise endurance time compared with placebo which was associated with sustained reductions of lung hyperinflation as indicated by significant improvement in IC at rest and during exercise. " 10/01/2013 - "Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study." 01/01/2015 - "In this double-blind, double-dummy, parallel-group study, 744 patients with moderate-to-severe COPD with a history of ≤1 exacerbations in the previous year were randomized (1:1) to QVA149 110/50 μg once daily or SFC 50/500 μg twice daily for 26 weeks. " 01/01/2015 - "The eDiary was completed by a subset of 209 patients with moderate-to-severe COPD in the 26-week QVA149 SHINE study. " 06/01/2014 - "Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study."
2.	Dyspnea (Shortness of Breath) 01/01/2015 - "QVA149 and SFC had similar improvements in transition dyspnea index focal score, St George Respiratory Questionnaire total score, and rescue medication use. " 01/01/2015 - "This post hoc analysis evaluated the improvements in lung function, dyspnea, and health status in subgroups of patients based on prior medication use, disease severities, baseline cough score, and baseline rescue medication use, achieved with QVA149 compared with placebo and other active comparators in 2 phase III clinical studies. " 01/01/2015 - "QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies." 04/01/2015 - "QVA149 is non-inferior to TIO+FOR in improving HRQoL, with clinically meaningful and significant improvements in breathlessness and lung function in patients with COPD. " 01/01/2015 - "Conclusion: QVA149 showed improvements in lung function, dyspnea, and health status in both moderate and severe COPD patients independent of previous medication use and baseline cough score."
3.	Pneumonia (Pneumonitis) 01/01/2015 - "The incidence of pneumonia was threefold lower with QVA149 (0.8%) versus SFC (2.7%). " 10/01/2014 - "The HR for QVA149 versus placebo showed no significant increase in the overall risk for death (HR [95% confidence interval]: 0.93 [0.34-2.54]); CCV events (0.60 [0.29-1.24]); MACE (1.04 [0.45-2.42]); pneumonia (1.10 [0.54-2.25]); COPD exacerbations (0.60 [0.40-0.91]); and AF/F (1.03 [0.49-2.18]). " 01/01/2015 - "Our meta-analysis indicated that QVA149 is superior to the salmeterol-fluticasone combination to treat COPD in respect of the frequency of adverse effects, exacerbation, pneumonia, and improvement of trough forced expiratory volume in 1 second (FEV1). "
4.	Respiratory Insufficiency (Respiratory Failure) 01/01/2018 - "We report our experience with a patient suffering from severe respiratory failure who improved significantly when the indacaterol/glycopyrronium combination was added to his therapy."
5.	Cough 01/01/2015 - "QVA149 showed significant improvements in lung function compared with placebo (SHINE study) and SFC (ILLUMINATE study) regardless of prior medication, disease severity, baseline cough score, and rescue medication use. " 01/01/2015 - "This post hoc analysis evaluated the improvements in lung function, dyspnea, and health status in subgroups of patients based on prior medication use, disease severities, baseline cough score, and baseline rescue medication use, achieved with QVA149 compared with placebo and other active comparators in 2 phase III clinical studies. " 01/01/2015 - "Conclusion: QVA149 showed improvements in lung function, dyspnea, and health status in both moderate and severe COPD patients independent of previous medication use and baseline cough score."

Related Drugs and Biologics

1.	Glycopyrrolate (Glycopyrronium Bromide)
2.	indacaterol
3.	Tiotropium Bromide (Spiriva)
4.	Bronchodilator Agents (Bronchodilators)
5.	Muscarinic Antagonists
6.	Salmeterol Xinafoate (Serevent)
7.	Fluticasone (Cutivate)
8.	Gold
9.	Adrenal Cortex Hormones (Corticosteroids)
10.	Formoterol Fumarate (Oxis)

Related Therapies and Procedures

1.	Therapeutics
2.	Nebulizers and Vaporizers (Inhaler)